In Friday’s after-hours trading, Exscientia plc (NASDAQ: EXAI) shares increased 8.32% to $6.90 after the business announced a strategic partnership.
EXAI has launched what?
Today, Exscientia (EXAI) and The University of Texas MD Anderson Cancer Center announced a strategic partnership to advance cutting-edge small-molecule oncology treatments by combining Exscientia’s patient-centric artificial intelligence (AI) capabilities with MD Anderson’s expertise in drug discovery and development.
Based on collaboratively determining therapeutic targets, the research cooperation will make use of EXAI’s precision medicine platform to find new anti-cancer, cell-intrinsic small-molecule compounds. Candidates who show promise will move on to further training with the Therapeutics Discovery team at MD Anderson. Successful target discovery projects may be advanced into MD Anderson proof-of-concept clinical trials, according to the collaborators.
MD Anderson is driven to provide the newest cancer therapies that can significantly help patients and enhance their quality of life. This partnership is based on the power of MD Anderson’s drug discovery and development engine, the proficiency of its clinical research teams, and the AI-driven precision medicine platform of EXAI. MD Anderson’s ultimate objective is to shorten the time it takes to develop new targeted medicines and hasten their clinical introduction.
EXAI will work with the IACS team to create new small-molecule therapies, which is a drug discovery engine. IACS is a key element of MD Anderson’s Therapeutics Discovery division, a team of integrated researchers, medical professionals, and experts in drug development that advances important new therapies.
Exscientia (EXAI) will collaborate with MD Anderson to use its AI-driven platform for the development of cutting-edge cancer therapies. Through the application of deep learning multi-omics inside our precision medicine platform, EXAI is able to test possible drug candidates in Exscientia’s patient tissue models, opening up new avenues for cancer research.
How will EXAI continue to excel?
The EXAI platform has the ability to stratify patients even in the early stages of discovery, enabling the business to quickly create drug candidates that are most likely to have a positive impact on cancer patients. Exscientia (EXAI) and MD Anderson shall collaborate on and support any initiative that is chosen to advance in accordance with the conditions of the agreement.